Viennese Prevalence Study of Anderson-Fabry Disease (VIEPAF)
Recruitment status was Active, not recruiting
The prevalence of Anderson - Fabry disease in patients with left ventricular hypertrophy is unclear. The investigators will examine urine - α - Galactosidase activity and globotriaosylceramide isoforms in these patients.
Left Ventricular Hypertrophy
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Prevalence of Anderson - Fabry Disease in Patients With Left Ventricular Hypertrophy|
- Prevalence of Anderson - Fabry disease [ Time Frame: 2 years ] [ Designated as safety issue: No ]
Biospecimen Retention: Samples Without DNA
|Study Start Date:||January 2009|
|Estimated Study Completion Date:||January 2012|
|Estimated Primary Completion Date:||January 2012 (Final data collection date for primary outcome measure)|
Anderson - Fabry disease (AFD) is a rare, X - linked hereditary systemic lysosomal storage disorder which usually affects the heart. The reported incidence of AFD is between 1 in 117000 and 1 in 240000 live births. Due to a deficiency of the enzyme α - galactosidase, glycosphingo-lipids, primarily globotriaosylceramide, are stored also in endothelial and myocardial cells, leading to morphologic and functional changes. AFD-cardiomyopathy progresses with age and with the course of the disease, leading to reduced life expectancy. The investigators hypothesize, that AFD could be underdiagnosed in patients with only mild or moderate left ventricular myocardial hypertrophy. Early diagnosis of AFD may be relevant since affected patients might benefit from enzyme replacement therapy at early stage of disease. The investigators will examine 4000 consecutive patients with an echocardiographically measured interventricular septum thickness of ≥ 12mm. Urine samples will be collected and Gb3-isoforms, creatinine and α - Galactosidase activity will be measured.
|Department of Internal Medicine II, Div. Cardiology, Vienna General Hospital|
|Vienna, Austria, 1090|
|Principal Investigator:||Gerald Mundigler, MD||Medical University of Vienna, Dept. Internal Medicine, Cardiology|